UroAmp Photocure Studie

Offentlig prosjektsammendrag

This project aims to improve outcomes for patients with high-risk non-muscle invasive bladder cancer by combining Blue Light Cystoscopy (BLC) with UroAmp urinary genomic profiling. Despite standard treatment, recurrence and progression rates remain high. BLC enhances tumor detection using a fluorescent contrast agent, while UroAmp uses next-generation sequencing to detect DNA mutations from urine samples and predict recurrence risk. The project will be implemented as a prospective, randomized controlled trial involving 200 patients. Urine samples will be collected at multiple time points to assess minimal residual disease and long-term outcomes. The goal is to validate a new, integrated clinical pathway that enables more accurate diagnosis, personalized monitoring, and earlier intervention, potentially setting a new standard in bladder cancer care.